PE 22-28 10mg

TREK-1 (TWIK-related K+ channel 1, KCNK2) is a two-pore-domain "background" potassium channel that sets the resting membrane potential in neurons and is modulated by temperature, mechanical stretch, lipids, and various neurotransmitter signaling. TREK-1 knockout mice show reduced depression-like behavior and resistance to stress-induced anhedonia. Conventional antidepressants including SSRIs and tricyclics partially inhibit TREK-1 in addition to their primary targets. This led to the hypothesis that TREK-1 inhibition contributes to antidepressant efficacy, and spadin/PE-22-28 allow testing this hypothesis with more selective TREK-1 antagonists.

Published rodent studies by Mazella's group and others have shown PE-22-28 produces antidepressant-like effects in standard behavioral tests (forced swim test, tail suspension test) and in chronic mild stress models. The effects were observed at IP or IV doses and appeared to involve TREK-1-related mechanisms. The compound also showed effects on hippocampal neurogenesis in some studies. All evidence is preclinical -- no clinical trials in humans have been conducted. The data supports PE-22-28 as a useful tool for TREK-1 research in mood biology contexts.

Conventional antidepressants (SSRIs, SNRIs, tricyclics) affect multiple targets -- monoamine transporters, various receptors, and ion channels including TREK-1. This polypharmacology makes it difficult to attribute specific effects to TREK-1 modulation. PE-22-28's relative selectivity for TREK-1 makes it more useful for determining which antidepressant-related effects are specifically TREK-1-mediated versus those requiring monoaminergic mechanisms. This specificity is valuable for mechanistic research even if PE-22-28 is not being developed as a clinical antidepressant itself.